125 results about "Cell targeting" patented technology

The application provides an improved hyaluronic acid injection preparation for inflammation targeting and stem cell capture, a preparation method and use thereof, and belongs to the field of medicine. The injection preparation is prepared from unsaturated bond modified hyaluronic acid, stem cell targeting DNA tetrahedron and thiol modified inflammation targeting aptamer as raw materials. The injection preparation can be targeted to accumulate at an osteoarthritis site, capture mesenchymal stem cells in situ, recruit mesenchymal stem cells to the osteoarthritis site, promote differentiation of stem cells into cartilage, promote cartilage repair, play a role in treating osteoarthritis, and has a good application prospect.

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The invention relates to a CAR-T (Chimeric Antigen Receptor-T) cell targeting SLC7A11.

The invention discloses a regulation mechanism research method of depleted precursor CD8T cells, and relates to the field of immunology and molecular biology. Comprising the following steps: detecting the expression level of the ARHGAP9 gene in a chronic virus infection model; constructing a T cell specific ARHGAP9 gene knockout animal model; the influence of ARHGAP9 deletion on the frequency, phenotype and function of the Tpex cell is analyzed; a single cell transcriptome sequencing technology reveals that ARHGAP9 regulates and controls a downstream signal channel of a Tpex cell. By constructing a chronic virus infection model, detecting the expression dynamic state of the ARHGAP9 gene, knocking out an animal model by utilizing T cell specificity ARHGAP9, and combining flow cytometry, qPCR, single cell transcriptome sequencing and other technologies, the invention discloses the effect of the ARHGAP9 as a novel immune checkpoint molecule, and provides a theoretical basis for developing Tpex cell targeting immunotherapy.

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

The invention relates to the technical field of production of nano composite materials, in particular to space heterostructure ferrite nano particles with a hepatocyte targeting function and a preparation method of the space heterostructure ferrite nano particles. According to the nanoparticles, a core layer and a shell layer are doped with metal elements in a gradient manner, and a ligand layer with a hepatocyte targeting function is modified, so that a physical-chemical three-layer composite system with a spatial heterostructure is formed. According to the magnetic resonance imaging contrast agent prepared on the basis of the spatial heterogeneous distribution of gradient doping of the ferrite nanoparticles by regulating and controlling the types and concentrations of doping elements, the enrichment effect and the local recognition capability in a liver region can be remarkably enhanced, the relaxation rate of the ferrite nanoparticles is effectively increased, and the magnetic resonance imaging contrast agent has a good application prospect. The contrast ratio, the imaging speed and the effective imaging time window of living liver and gall imaging are optimized, and meanwhile, the biocompatibility and the metabolic performance of the material are improved.

Disclosed is a method for editing mitochondrial DNA (mtDNA) within a cell, which include introducing into the cell (a) a DNA cleaving enzyme targeted to the mtDNA sequence to be deleted; (b) a first DNA binding component targeted to a sequence adjacent to the 5′ end of a mtDNA sequence to be deleted; and (c) a second DNA binding component targeted to a sequence adjacent to the 3′ end of the mtDNA sequence to be deleted, where the DNA cleaving enzyme generates a double stranded break (DSB) within the mtDNA sequence to be deleted or generates a single strand nick on the light strand of the mtDNA sequence to be deleted, and wherein the mtDNA sequence between the target sequence for the first DNA binding component and the target sequence for the second DNA binding component is deleted.

Provided herein are compositions comprising a muscle (cardiac and / or skeletal) cell targeting peptide linked to or inserted into a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn-RGD-n-mer-Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors with engineered capsid or envelope proteins are provided, along with uses thereof.

Embodiments of the invention disclosed herein involve the selective engineering of Sindbis virus so as to generate cells that make enveloped virus-like particles that contain therapeutic mRNAs, and whose membrane proteins have been mutated to serve as modular binding sites for cell-targeting ligands.

Provided herein are immuno-responsive cells expressing a B cell targeting pCAR comprising a 2nd generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immuno-responsive cells and methods of directing T cell mediated immune response using the immuno-responsive cells.

This invention relates to a polypeptide for gene delivery, a polypeptide / nucleic acid molecular complex prepared therefrom, and its applications. The polypeptide of this application has the structure shown in Formula I, wherein Formula I contains an immune cell targeting group represented by Y. The polypeptide developed in this application, as a gene delivery carrier, has a highly efficient nucleic acid loading capacity. Furthermore, it exhibits high delivery efficiency to immune cells both in vitro and in vivo, thus showing broad application prospects in the immune cell-targeted delivery of genes.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

The invention discloses a coupling molecule with an effect of promoting macrophages to selectively swallow extracellular goods as well as a preparation method and application of the coupling molecule, and belongs to the technical field of biological medicines. The coupling molecule disclosed by the invention is a double-targeting polypeptide and consists of a macrophage targeting peptide fragment, a linker and a target cell targeting peptide fragment, wherein the target cell targeting peptide fragment comprises peptide fragments targeting tumor cells and apoptotic cells. One end of the dual-targeting polypeptide is connected with macrophages, the other end of the dual-targeting polypeptide is connected with tumor cells / apoptotic cells, and the interaction between the macrophages and the tumor cells / apoptotic cells is improved in a molecular glue mode. Aiming at tumor cells, the dual-targeting polypeptide can enhance the phagocytosis and killing effects of macrophages on the tumor cells under the action of a CD47 antibody, so that the anti-tumor effect is achieved; aiming at apoptotic cells, the dual-targeting polypeptide can promote the interplant effect of macrophages, so that the anti-inflammatory effect is achieved. Therefore, the dual-targeting polypeptide disclosed by the invention has relatively good drug development potential.

This invention discloses an antibody-engineered bone marrow stromal cell and its applications, belonging to the field of biomedical technology. Using bone marrow stromal cells as a biological carrier, this invention externally modifies them with immune checkpoint antibodies to form an antibody-coated engineered cell preparation, thereby achieving targeted and precise mitochondrial delivery of exhausted T cells. This cell preparation can be used in combination with other immunotherapies that can induce T cell exhaustion, such as tumor immunotherapies and CAR-T therapy, to help enhance their anti-tumor efficacy and duration of effect.

A method for marking cancer-associated mutations includes applying a nanoparticle having cell-targeting moiety containing an miRNA associated with a specific cancer.

The present application relates to the technical field of biological agents, and discloses a kind of M cell targeted peptide and chitosan modified dendritic mesoporous silica oral adjuvant and application thereof.The oral adjuvant includes dendritic mesoporous silica (DFNSs), and M cell targeted peptide (CKS9) modified chitosan (CS), the dendritic mesoporous silica is mixed with M cell targeted peptide modified chitosan at mass ratio 4-6:1, and is made into CKS9-CS-DFNSs oral nano adjuvant.The CKS9-CS-DFNSs oral nano adjuvant provided in the present application has good stability and safety, can effectively induce mucosal immune response and humoral immune response by oral immunization, improve the effect of oral vaccine immunization, and can be widely used in the preparation of animal inactivated vaccine, recombinant protein vaccine and polypeptide vaccine.The oral nano adjuvant preparation has low cost, simple process and is easy to mass-produce.

To provide cells containing anti-CD33 chimeric antigen receptors (CARs); anti-CLL1 CARs; and anti-CD123 and / or anti-CAR FLT3 CARs. [Solution] The aforementioned cells can be used in the treatment of diseases such as acute myeloid leukemia (AML). In a first aspect, the present invention provides CAR-expressing cells that target multiple antigens associated with acute myeloid leukemia (AML). These cells target three or four of the following antigens: CD33, CLL-1, CD123, and FLT3. For example, the cells may include anti-CD33 chimeric antigen receptor (CAR); anti-CLL1 CAR; and anti-CD123 CAR.

The invention discloses a bispecific antibody fusion protein, a recombinant oncolytic virus and application of the bispecific antibody fusion protein and the recombinant oncolytic virus in preparation of drugs for treating tumors, the recombinant oncolytic virus can express and secrete a bispecific antibody HER2-BiTE, and the bispecific antibody HER2-BiTE can serve as an adapter to recruit T cell targeted HER2 positive tumor cells, so that the killing effect of the T cells on the tumor cells is improved; meanwhile, the oncolytic virus causes tumor cell lysis, tumor-associated antigen release and tumor microenvironment remodeling; the BiTE plays a role in tumor sites, so that the adverse reaction of systemic administration is relieved. The synergistic effect of the oncolytic virus and the bispecific antibody improves the tumor treatment effect.

Provided are transferrin receptor binding VHH domains as well as delivery complexes and methods for targeting cells of interest for delivery of an active cargo such as an oligomeric agent. In particular, the delivery complex may comprise modified Fc domain and a transferrin receptor binding VHH domain.

The invention discloses a pericyte targeting active peptide and application thereof in preparation of antitumor drugs, and relates to the technical field of medicines. The percutaneous cell targeting active peptide is obtained by condensation of NKX2-3 fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP), and the fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP) are respectively Z-GP-NB1, Z-GP-NB2, Z-GP-NB3, Z-GP-NB4 The percutaneous cell targeting active peptide can effectively block the transcriptional activity of NKX2-3, recover the contractility of tumor percutaneous cells and enhance the local vascular tension of tumors, so that the tumor distal metastasis is inhibited, and the percutaneous cell targeting active peptide is expected to be applied to the treatment of patients with malignant tumors accompanied by the distal metastasis.

The invention provides an application method of a PPAR gamma agonist in preparation of a medicine for inhibiting ferroptosis of nucleus pulposus cells, and belongs to the technical field of medicine preparation.The PPAR gamma agonist pioglitazone and TAT cell-penetrating peptide are combined to form a compound, the compound is encapsulated in hyaluronic acid modified pH-sensitive lipidosome to construct a nucleus pulposus targeted drug delivery system, and the nucleus pulposus targeted drug delivery system is used for inhibiting ferroptosis of the nucleus pulposus cells. The flow cytometry is utilized to detect the physicochemical properties of the drug delivery system, the optimal drug delivery parameters are determined through a double-layer game optimization model, the drug release kinetics is determined in different pH environments to establish a pH response release model, and finally the PPAR gamma and Axl protein expression levels and the GPX4 protein level are detected through the fluorescence luminescence to verify the ferroptosis resisting effect. The technical problem that a drug carrier system cannot realize dual-function collaborative optimization of targeted delivery and acid-sensitive controlled release of nucleus pulposus cells is solved.

The invention belongs to the field of biological medicine, and particularly discloses a method for preparing nanoparticles NCTD-LpEV-cRGD by adopting bacterial extracellular vesicles (LpEV) derived from lactobacillus paracasei to entrap tumor chemotherapeutic drug norcantharidin (NCTD) and modifying tumor targeting peptide cRGD on the surface of the LpEV. An anti-colorectal cancer effect test research shows that the NCTD-coated LpEV-cRGD nanoparticle can simultaneously exert a colorectal cancer cell targeting effect and an anti-colorectal cancer proliferation and metastasis effect, so that the anti-colorectal metastasis curative effects of chemotherapeutic drugs norcantharidin and bacterial extracellular vesicles are remarkably enhanced, and the NCTD-coated LpEV-cRGD nanoparticle has good safety. The NCTD-coated LpEV-cRGD nanoparticles prepared by the preparation method disclosed by the invention can be used for preparing medicines for resisting colorectal metastasis.

The application provides a cell-targeting drug primary screening model training method, a drug primary screening method and equipment. The method comprises the following steps: obtaining molecular fingerprint feature data corresponding to each compound sample with label information to form a corresponding original data set, performing data screening on the original data set by using a distance measurement method, and training a regression model based on a graph neural network to learn the structure topology of each compound sample. The model is trained as a cell-targeting drug primary screening model for predicting whether a compound has potential cell-targeting drug activity. The application can effectively improve the comprehensiveness of molecular representation during the training process of the cell-targeting drug primary screening model, effectively improve the generalization ability of the cell-targeting drug primary screening model obtained by training, effectively improve the applicability of the cell-targeting drug primary screening model obtained by training, and improve the accuracy and reliability of the prediction result of the potential cell-targeting drug activity predicted by the model.

The present disclosure provides delivery particles comprising: (a) a targeting moiety on the surface of the particle, wherein the targeting moiety comprises an antibody or an antigen-binding fragment thereof that binds to a T cell antigen selected from CD5, CD7, and CD27; and (b) a payload encapsidated within the particle. The disclosure provides methods of using the particles.

The invention relates to the technical field of medicines, and particularly discloses a medicine and a method for treating diseases caused by autoantibodies generated by excessive proliferation of B cells and application of the medicine and the method. The medicine for treating the diseases caused by autoantibodies generated by excessive proliferation of B cells comprises mRNA (messenger Ribonucleic Acid) for coding chimeric antigen receptor molecules and T cell targeting lipid nanoparticles, the drug can generate chimeric antigen receptor T cells in vivo; the lipid nanoparticles comprise cationic lipid, phospholipid, cholesterol, PEG lipid and targeting molecules, and the targeting molecules mediate T cell targeting. Lipid nanoparticles (mRNA-LNP) encapsulating chimeric antigen receptor molecules mRNA are used for delivering mRNA into in-vivo T cells to generate chimeric antigen receptor T cells, and pathological autoreactive B cells are removed to treat diseases caused by autoantibodies generated by excessive proliferation of the B cells.

Methods and compositions relate to managing chimeric antigen receptor T (CAR T) cell therapy-associated diarrhea in human subjects undergoing such therapy for colorectal cancer (CRC) are disclosed. The CAR T cells target a CRC-associated antigen, such as Guanylate Cyclase C (GCC) or Carcinoembryonic Antigen (CEA). The methods comprise administering a prophylactic regimen to the subject post-infusion of CAR T cells. This regimen includes agents such as vedolizumab, infliximab, or prophylactic budesonide. Subjects are monitored for diarrhea development and severity based on predefined clinical criteria, including stool frequency or stool volume. The methods may further involve a tiered therapeutic algorithm for treating occurring diarrhea, potentially utilizing corticosteroids or antithymocyte globulin (ATG). These approaches aim to reduce the incidence, duration, and severity of CAR T induced diarrhea, thereby improving patient safety and treatment tolerability.

The application discloses a recombinant membrane-targeting type 17 collagen protein and application thereof. The application realizes gene fusion of a COL17A1 key function domain and an independent membrane-targeting structure domain for the first time, constructs a novel "activity-targeting" integrated recombinant membrane-targeting type 17 collagen protein (M-C17a1), effectively integrates function activity and cell targeting property through ingenious structure design, and exhibits excellent performance in resisting skin aging, tissue repair and promoting hair growth. The application also proposes a complete preparation method based on a Pichia pastoris expression system. The expression system has high-density fermentation capacity and secretory expression characteristics, significantly simplifies a purification process, and has relatively low production cost, so that the expression system is suitable for large-scale production of the recombinant protein and has good industrial application prospect.

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

A labeled cell targeting agent for in vivo imaging of a subject is disclosed. The labeled cell targeting includes, for example, a radiolabel or a paramagnetic ion or compound or a labeling agent-binding moiety; and a polypeptide comprising an IL13 or mIL13 amino acid sequence that binds IL13Rα2 and optionally a PE cytotoxin amino acid sequence. Methods of preparing and using the agent also are provided. The labeled cell targeting agent may be used in a method of in vivo imaging, wherein the method comprises administering the labeled therapeutic agent to a subject such that a cell of the subject becomes labeled for in vivo imaging, wherein the cell may be an IL13Rα2-expressing cell, such as a diffuse midline glioma cell or a glioblastoma cell.